June 2013 | Oncology Live®

July 25, 2013

When Jimmie C. Holland, MD, conducts research, geriatric cancer patients are often her focus. Holland has studied telephone intervention as a way to monitor stress in patients aged 65 and older. She discussed the effort with OncologyLive.

July 22, 2013

Over the past decade, it has become apparent that head and neck squamous cell carcinoma-including cancers of the mouth, throat, and larynx-is actually two separate diseases.

July 19, 2013

An Interview With Jimmie C. Holland, MD, on her research and role in the development of a vital area of cancer care.

July 17, 2013

Albert S. Baldwin, Jr, PhD, focuses on understanding the regulation and biological functions of NF-κB and its role in disease, particularly in cancer, in a laboratory he heads at the UNC Lineberger Comprehensive Cancer Center.

July 09, 2013

Should an individual patient be denied the opportunity to potentially achieve the benefits from a therapeutic strategy because it is predicted that his or her tumor will have a relatively low chance to respond?

July 08, 2013

Recently published clinical trial results support new radiation therapy protocols for many breast cancer survivors⎯protocols that could greatly improve collective outcome.

July 02, 2013

The translation of scientific advances in nanotechnology into cancer therapies, in vitro assays, and imaging tools is poised for takeoff, amid fresh excitement among investors and a mushrooming of findings from leading research institutions.

June 28, 2013

The complex regulation of NF-κB activation has presented significant challenges for the development of anticancer agents, but researchers are now beginning to better understand and embrace this complexity to drive development of a variety of novel NF-κB-targeting strategies.

June 21, 2013

In an interview with OncologyLive, Brian G.M. Durie, MD, provided details about the Black Swan initiative and how he expects the project to develop.

June 21, 2013

Progression-free survival doubled in men with metastatic castration-resistant prostate cancer with no chemotherapy exposure who were treated with abiraterone acetate plus prednisone versus prednisone alone.

June 18, 2013

Clinical judgment may appropriately decide that based on a particular patient's medical status it may not be in that individual's best interest to undergo guideline-based therapy.